In our evaluation of the effects of the HAMLET complex on different CRC cell lines (HT-29 and WiDr (a derivative of HT-29)) with V600E BRAF mutation status, we found consistent dose-dependent effects on viability at 2 μM, 5 μM, 10 μM, and 20 μM concentrations. Here, BRAF is linked to colorectal carcinoma.